These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

401 related articles for article (PubMed ID: 22120678)

  • 1. Hsp90 inhibitors and drug resistance in cancer: the potential benefits of combination therapies of Hsp90 inhibitors and other anti-cancer drugs.
    Lu X; Xiao L; Wang L; Ruden DM
    Biochem Pharmacol; 2012 Apr; 83(8):995-1004. PubMed ID: 22120678
    [TBL] [Abstract][Full Text] [Related]  

  • 2. HSP90 inhibition is effective in breast cancer: a phase II trial of tanespimycin (17-AAG) plus trastuzumab in patients with HER2-positive metastatic breast cancer progressing on trastuzumab.
    Modi S; Stopeck A; Linden H; Solit D; Chandarlapaty S; Rosen N; D'Andrea G; Dickler M; Moynahan ME; Sugarman S; Ma W; Patil S; Norton L; Hannah AL; Hudis C
    Clin Cancer Res; 2011 Aug; 17(15):5132-9. PubMed ID: 21558407
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Carbamazepine promotes Her-2 protein degradation in breast cancer cells by modulating HDAC6 activity and acetylation of Hsp90.
    Meng Q; Chen X; Sun L; Zhao C; Sui G; Cai L
    Mol Cell Biochem; 2011 Feb; 348(1-2):165-71. PubMed ID: 21082217
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Histone deacetylase activity mediates acquired resistance towards structurally diverse HSP90 inhibitors.
    Chai RC; Vieusseux JL; Lang BJ; Nguyen CH; Kouspou MM; Britt KL; Price JT
    Mol Oncol; 2017 May; 11(5):567-583. PubMed ID: 28306192
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hsp90 inhibitor 17-AAG reduces ErbB2 levels and inhibits proliferation of the trastuzumab resistant breast tumor cell line JIMT-1.
    Zsebik B; Citri A; Isola J; Yarden Y; Szöllosi J; Vereb G
    Immunol Lett; 2006 Apr; 104(1-2):146-55. PubMed ID: 16384610
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Why is this effective HSP90 inhibitor not being developed in HER2+ breast cancer?
    Arteaga CL
    Clin Cancer Res; 2011 Aug; 17(15):4919-21. PubMed ID: 21670086
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Possible effects of early treatments of hsp90 inhibitors on preventing the evolution of drug resistance to other anti-cancer drugs.
    Xiao L; Rasouli P; Ruden DM
    Curr Med Chem; 2007; 14(2):223-32. PubMed ID: 17266581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preclinical antitumor activity of the novel heat shock protein 90 inhibitor CH5164840 against human epidermal growth factor receptor 2 (HER2)-overexpressing cancers.
    Ono N; Yamazaki T; Nakanishi Y; Fujii T; Sakata K; Tachibana Y; Suda A; Hada K; Miura T; Sato S; Saitoh R; Nakano K; Tsukuda T; Mio T; Ishii N; Kondoh O; Aoki Y
    Cancer Sci; 2012 Feb; 103(2):342-9. PubMed ID: 22050138
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Antitumor activity of the Hsp90 inhibitor IPI-504 in HER2-positive trastuzumab-resistant breast cancer.
    Scaltriti M; Serra V; Normant E; Guzman M; Rodriguez O; Lim AR; Slocum KL; West KA; Rodriguez V; Prudkin L; Jimenez J; Aura C; Baselga J
    Mol Cancer Ther; 2011 May; 10(5):817-24. PubMed ID: 21383049
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hsp90 inhibition and co-incubation with pertuzumab induce internalization and degradation of trastuzumab: Implications for use of T-DM1.
    Skeie M; Nikolaysen F; Chitano Y; Stang E
    J Cell Mol Med; 2020 Sep; 24(17):10258-10262. PubMed ID: 32672902
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Inhibitors of HSP90 block p95-HER2 signaling in Trastuzumab-resistant tumors and suppress their growth.
    Chandarlapaty S; Scaltriti M; Angelini P; Ye Q; Guzman M; Hudis CA; Norton L; Solit DB; Arribas J; Baselga J; Rosen N
    Oncogene; 2010 Jan; 29(3):325-34. PubMed ID: 19855434
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combination of trastuzumab and tanespimycin (17-AAG, KOS-953) is safe and active in trastuzumab-refractory HER-2 overexpressing breast cancer: a phase I dose-escalation study.
    Modi S; Stopeck AT; Gordon MS; Mendelson D; Solit DB; Bagatell R; Ma W; Wheler J; Rosen N; Norton L; Cropp GF; Johnson RG; Hannah AL; Hudis CA
    J Clin Oncol; 2007 Dec; 25(34):5410-7. PubMed ID: 18048823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. DCZ3112, a novel Hsp90 inhibitor, exerts potent antitumor activity against HER2-positive breast cancer through disruption of Hsp90-Cdc37 interaction.
    Chen X; Liu P; Wang Q; Li Y; Fu L; Fu H; Zhu J; Chen Z; Zhu W; Xie C; Lou L
    Cancer Lett; 2018 Oct; 434():70-80. PubMed ID: 30017966
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lapatinib and 17AAG reduce 89Zr-trastuzumab-F(ab')2 uptake in SKBR3 tumor xenografts.
    Oude Munnink TH; de Vries EG; Vedelaar SR; Timmer-Bosscha H; Schröder CP; Brouwers AH; Lub-de Hooge MN
    Mol Pharm; 2012 Nov; 9(11):2995-3002. PubMed ID: 23003202
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Breast cancer and HSP90 inhibitors: is there a role beyond the HER2-positive subtype?
    De Mattos-Arruda L; Cortes J
    Breast; 2012 Aug; 21(4):604-7. PubMed ID: 22560618
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antitumor efficacy of IPI-504, a selective heat shock protein 90 inhibitor against human epidermal growth factor receptor 2-positive human xenograft models as a single agent and in combination with trastuzumab or lapatinib.
    Leow CC; Chesebrough J; Coffman KT; Fazenbaker CA; Gooya J; Weng D; Coats S; Jackson D; Jallal B; Chang Y
    Mol Cancer Ther; 2009 Aug; 8(8):2131-41. PubMed ID: 19671750
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hsp90 inhibitor as a sensitizer of cancer cells to different therapies (review).
    Solárová Z; Mojžiš J; Solár P
    Int J Oncol; 2015 Mar; 46(3):907-26. PubMed ID: 25501619
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Marked enhancement of lysosomal targeting and efficacy of ErbB2-targeted drug delivery by HSP90 inhibition.
    Raja SM; Desale SS; Mohapatra B; Luan H; Soni K; Zhang J; Storck MA; Feng D; Bielecki TA; Band V; Cohen SM; Bronich TK; Band H
    Oncotarget; 2016 Mar; 7(9):10522-35. PubMed ID: 26859680
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of HSP90 with AUY922 induces synergy in HER2-amplified trastuzumab-resistant breast and gastric cancer.
    Wainberg ZA; Anghel A; Rogers AM; Desai AJ; Kalous O; Conklin D; Ayala R; O'Brien NA; Quadt C; Akimov M; Slamon DJ; Finn RS
    Mol Cancer Ther; 2013 Apr; 12(4):509-19. PubMed ID: 23395886
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The HSP90 inhibitor HVH-2930 exhibits potent efficacy against trastuzumab-resistant HER2-positive breast cancer.
    Park M; Jung E; Park JM; Park S; Ko D; Seo J; Kim S; Nam KD; Kang YK; Farrand L; Hoang VH; Nguyen CT; La MT; Nam G; Park HJ; Ann J; Lee J; Kim YJ; Kim JY; Seo JH
    Theranostics; 2024; 14(6):2442-2463. PubMed ID: 38646654
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 21.